CA2309688A1 - Penetration enhancing and irritation reducing systems - Google Patents
Penetration enhancing and irritation reducing systems Download PDFInfo
- Publication number
- CA2309688A1 CA2309688A1 CA002309688A CA2309688A CA2309688A1 CA 2309688 A1 CA2309688 A1 CA 2309688A1 CA 002309688 A CA002309688 A CA 002309688A CA 2309688 A CA2309688 A CA 2309688A CA 2309688 A1 CA2309688 A1 CA 2309688A1
- Authority
- CA
- Canada
- Prior art keywords
- penetration enhancing
- irritation reducing
- reducing systems
- transdermal
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035515 penetration Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000007794 irritation Effects 0.000 title 1
- 238000012377 drug delivery Methods 0.000 abstract 2
- 230000000699 topical effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin imitation that often accompanies transdermal and topical drug delivery.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6498097P | 1997-11-10 | 1997-11-10 | |
US60/064,980 | 1997-11-10 | ||
PCT/US1998/023750 WO1999024041A1 (en) | 1997-11-10 | 1998-11-09 | Penetration enhancing and irritation reducing systems |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2309688A1 true CA2309688A1 (en) | 1999-05-20 |
CA2309688C CA2309688C (en) | 2007-04-24 |
Family
ID=22059554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002309688A Expired - Fee Related CA2309688C (en) | 1997-11-10 | 1998-11-09 | Penetration enhancing and irritation reducing systems |
Country Status (17)
Country | Link |
---|---|
US (3) | US6319913B1 (en) |
EP (2) | EP1030668A4 (en) |
JP (2) | JP4139860B2 (en) |
KR (1) | KR100648536B1 (en) |
CN (1) | CN1172674C (en) |
AT (1) | ATE418988T1 (en) |
AU (1) | AU747041B2 (en) |
BR (1) | BR9814014B1 (en) |
CA (1) | CA2309688C (en) |
DE (1) | DE69840426D1 (en) |
DK (1) | DK1510213T3 (en) |
ES (1) | ES2318233T3 (en) |
IL (1) | IL136042A (en) |
NO (1) | NO20002422L (en) |
NZ (1) | NZ504423A (en) |
PT (1) | PT1510213E (en) |
WO (1) | WO1999024041A1 (en) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL136042A (en) * | 1997-11-10 | 2005-12-18 | Cellegy Pharma Inc | Alcohol-containing composition for topical application |
US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
ATE488233T1 (en) * | 2000-04-26 | 2010-12-15 | Watson Pharmaceuticals Inc | REDUCING SIDE EFFECTS OF OXYBUTYNIN THERAPY |
US7897559B2 (en) * | 2000-06-29 | 2011-03-01 | Parks L Dean | Dermatological composition and kit containing avermectin compound for treating dermatological conditions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
ES2283425T3 (en) | 2000-08-03 | 2007-11-01 | Antares Pharma Ipl Ag | NEW COMPOSITION FOR THE TRANSDERMAL AND / OR TRANSMUCTIVE ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURE ADEQUATE THERAPEUTIC LEVELS. |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US8980290B2 (en) * | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
MXPA03001859A (en) * | 2000-08-30 | 2004-05-21 | Unimed Pharmaceuticals Inc | Method of increasing testosterone and related steroid concentrations in women. |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
ATE460939T1 (en) * | 2000-08-30 | 2010-04-15 | Unimed Pharmaceuticals Llc | METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN |
JP5039252B2 (en) * | 2000-08-31 | 2012-10-03 | ユニメッド ファーマシューティカルズ,リミティド ライアビリティ カンパニー | Pharmaceutical compositions and methods for treating sexual dysfunction |
ES2283446T3 (en) * | 2000-12-22 | 2007-11-01 | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL | COMPOSITION OF GEL BASED ON ALCOHOL FOR THE TREATMENT OF HYPOGONADISM BY TRANSESCROTAL ADMINISTRATION. |
US20040176476A1 (en) * | 2001-06-22 | 2004-09-09 | Gyurik Robert J. | Pharmaceutical composition |
AU2002333193A1 (en) * | 2001-08-15 | 2003-03-03 | Leo Pharma A/S | A pharmaceutical composition for dermal application |
US20030175329A1 (en) * | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
AU2002366800B2 (en) | 2001-12-20 | 2006-08-03 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
IL163981A0 (en) * | 2002-03-15 | 2005-12-18 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method fortreating depression |
KR20050074896A (en) * | 2002-03-15 | 2005-07-19 | 유니메드 파마슈티칼스, 인크. | Androgen pharmaceutical composition and method for treating depression |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US6959640B2 (en) * | 2002-06-06 | 2005-11-01 | Omega Patents, L.L.C. | Device for magnetically treating materials and associated methods |
WO2004000263A1 (en) | 2002-06-25 | 2003-12-31 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
MXPA05004278A (en) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Cosmetic and pharmaceutical foam. |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
MXPA05007266A (en) | 2003-01-02 | 2006-01-17 | Femmepharma Holding Co Inc | Pharmaceutical preparations for treatments of diseases and disorders of the breast. |
FR2851470B1 (en) | 2003-02-20 | 2007-11-16 | Besins Int Belgique | PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY |
EP1594545B1 (en) * | 2003-02-20 | 2008-11-12 | Besins International Belgique | Pharmaceutical composition for transdermal or transmucosal administration |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
FR2856926B1 (en) * | 2003-07-02 | 2005-09-30 | Centre Nat Rech Scient | USE OF N-ALKANOLS AS ACTIVATORS OF THE CFTR CHANNEL |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
MXPA06003316A (en) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues. |
US20050244502A1 (en) * | 2004-04-28 | 2005-11-03 | Mathias Neil R | Composition for enhancing absorption of a drug and method |
US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
KR20130114229A (en) | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | Method and composition for transdermal drug delivery |
GB0518558D0 (en) * | 2005-09-12 | 2005-10-19 | Givaudan Sa | Improvements in or related to organic compounds |
NO346660B1 (en) | 2005-10-12 | 2022-11-21 | Unimed Pharmaceuticals Llc | Improved testosterone gel and method of use |
NZ571460A (en) | 2006-04-21 | 2010-10-29 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
EP2104489A2 (en) * | 2006-12-26 | 2009-09-30 | FemmePharma Holding Company, Inc. | Topical administration of danazol |
EP2106272A4 (en) | 2007-01-11 | 2011-05-04 | Acrux Dds Pty Ltd | Spreading implement |
US8759391B2 (en) * | 2007-01-16 | 2014-06-24 | Juventio, Llc | Topical anesthetic for rapid local anesthesia |
US9283177B2 (en) * | 2007-01-16 | 2016-03-15 | Juventio, Llc | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
WO2009143070A1 (en) * | 2008-05-21 | 2009-11-26 | Teikoku Pharma Usa, Inc. | Treatment of dysmenorrhea via transdermal administration of nonsteroidal anti-inflammatory drugs |
CA2730787A1 (en) * | 2008-07-16 | 2010-01-21 | David M. Cohen | Topical drug delivery system |
WO2010050889A1 (en) * | 2008-10-31 | 2010-05-06 | Moberg Derma Ab | Topical composition comprising a combination of at least two penetration enhancing agents |
EP2373305B1 (en) * | 2008-12-11 | 2017-03-15 | Besins Healthcare Luxembourg SARL | Transdermal pharmaceutical compositions comprising a serm |
WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
EP2467127B1 (en) | 2009-08-21 | 2023-08-02 | Novan, Inc. | Topical gels |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
CA2776474C (en) | 2009-10-02 | 2021-01-12 | Foamix Ltd. | Topical tetracycline compositions |
US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
CN102309669B (en) * | 2010-07-08 | 2013-07-03 | 高健生 | Chinese medicinal preparation for treating allergic conjunctivitis |
CA2818491A1 (en) | 2010-11-18 | 2012-05-24 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
KR20210135003A (en) * | 2011-05-15 | 2021-11-11 | 에이세러스 바이오파마 인크. | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
EP2729131B1 (en) | 2011-07-05 | 2020-04-15 | Novan, Inc. | Topical compositions |
CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
CN102335390B (en) * | 2011-09-30 | 2013-01-02 | 王巍 | Lotion for treating facial eczema |
BR112014021501B1 (en) | 2012-03-14 | 2020-12-08 | Novan, Inc | pharmaceutical composition for topical administration of a moisture-activated active pharmaceutical ingredient |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
US10206947B2 (en) | 2013-08-08 | 2019-02-19 | Novan, Inc. | Topical compositions and methods of using the same |
KR102321169B1 (en) | 2013-08-08 | 2021-11-02 | 노반, 인크. | Topical compositions and methods of using the same |
USD750788S1 (en) | 2013-11-26 | 2016-03-01 | Acrux Dds Pty Ltd | Topical spreading applicator |
USD749225S1 (en) | 2013-11-26 | 2016-02-09 | Acrux Dds Pty Ltd | Topical spreading applicator |
US8785426B1 (en) * | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
ES2807200T3 (en) | 2014-07-11 | 2021-02-22 | Novan Inc | Topical antiviral compositions and procedures for their use |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
US20170014417A1 (en) | 2015-07-14 | 2017-01-19 | Lipp Life Sciences Llc | Pharmaceutical administration system for the transdermal application of vardenafil |
EP3332787A4 (en) * | 2015-09-30 | 2018-08-01 | Fujifilm Corporation | Transdermally absorbable composition |
JP7090549B2 (en) | 2016-03-02 | 2022-06-24 | ノヴァン,インコーポレイテッド | Therapeutic compositions for inflammation and their treatment methods |
KR102426006B1 (en) | 2016-04-13 | 2022-07-29 | 노반, 인크. | Compositions, systems, kits, and methods for treating infections |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
AU2018205529B2 (en) | 2017-01-06 | 2023-08-10 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
WO2019169221A1 (en) | 2018-03-01 | 2019-09-06 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
AU2019365255A1 (en) | 2018-10-26 | 2021-06-03 | Viramal Limited | Mucoadhesive gel composition |
TW202305125A (en) | 2021-04-30 | 2023-02-01 | 美商凱立凡爾免疫治療股份有限公司 | Oncolytic viruses for modified mhc expression |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US175329A (en) * | 1876-03-28 | Improvement in processes of preserving burial-cases | ||
CA1165240A (en) | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
JPS59134710A (en) | 1983-01-21 | 1984-08-02 | Suntory Ltd | Hair tonic from fermentation product |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
JPS6067409A (en) | 1983-09-22 | 1985-04-17 | Suntory Ltd | Hair cosmetic |
US4743588A (en) * | 1984-06-13 | 1988-05-10 | Allergan Pharmaceuticals, Inc. | Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents |
US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
ATE77559T1 (en) * | 1986-11-14 | 1992-07-15 | Theratech Inc | INCREASE OF PENETRATION BY MEANS OF A BINARY SYSTEM CONSISTING OF CELL-CELL MODIFICATION SUBSTANCES AND SHORT-CHAIN ALCOHOLS. |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
DE68902753T2 (en) * | 1988-02-29 | 1993-01-21 | Pfizer | MEANS FOR INCREASING THE TRANSDERMAL PENETRATION FLOW. |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4855294A (en) | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
ZA899112B (en) * | 1988-12-01 | 1990-08-29 | Schering Corp | Compositions for transdermal delivery of estradiol |
EP0416173B1 (en) * | 1989-08-23 | 1997-01-15 | Hitachi, Ltd. | A method for adjusting network parameters in a multi-layer perceptron device, and perceptron device provided with means for executing the method |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
ES2153362T3 (en) * | 1991-08-26 | 2001-03-01 | Abbott Lab | COMPOSITIONS AND PROCEDURES OF SUBLINGUAL OR BUCAL ADMINISTRATION OF THERAPEUTIC AGENTS. |
ES2137993T3 (en) * | 1992-06-11 | 2000-01-01 | Theratech Inc | THE USE OF GLYCERINE TO MODERATE THE TRANSDERMAL CONTRIBUTION OF MEDICINES. |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
WO1995029678A1 (en) * | 1994-04-28 | 1995-11-09 | F.Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
WO1997024148A1 (en) * | 1995-12-29 | 1997-07-10 | Cygnus, Inc. | Systems and methods for the transdermal administration of androgenic agents |
IT1283102B1 (en) * | 1996-06-06 | 1998-04-07 | Permatec Nv | THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES |
US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
US5952000A (en) * | 1996-10-30 | 1999-09-14 | Theratech, Inc. | Fatty acid esters of lactic acid salts as permeation enhancers |
IL136042A (en) * | 1997-11-10 | 2005-12-18 | Cellegy Pharma Inc | Alcohol-containing composition for topical application |
US6465009B1 (en) | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
US20030175329A1 (en) | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
-
1998
- 1998-11-09 IL IL13604298A patent/IL136042A/en not_active IP Right Cessation
- 1998-11-09 KR KR1020007005094A patent/KR100648536B1/en active IP Right Grant
- 1998-11-09 WO PCT/US1998/023750 patent/WO1999024041A1/en active IP Right Grant
- 1998-11-09 CN CNB988130491A patent/CN1172674C/en not_active Expired - Fee Related
- 1998-11-09 EP EP98956663A patent/EP1030668A4/en not_active Withdrawn
- 1998-11-09 DE DE69840426T patent/DE69840426D1/en not_active Expired - Lifetime
- 1998-11-09 DK DK04028426T patent/DK1510213T3/en active
- 1998-11-09 EP EP04028426A patent/EP1510213B1/en not_active Revoked
- 1998-11-09 PT PT04028426T patent/PT1510213E/en unknown
- 1998-11-09 ES ES04028426T patent/ES2318233T3/en not_active Expired - Lifetime
- 1998-11-09 NZ NZ504423A patent/NZ504423A/en not_active IP Right Cessation
- 1998-11-09 JP JP2000520133A patent/JP4139860B2/en not_active Expired - Fee Related
- 1998-11-09 AT AT04028426T patent/ATE418988T1/en active
- 1998-11-09 BR BRPI9814014-0A patent/BR9814014B1/en not_active IP Right Cessation
- 1998-11-09 CA CA002309688A patent/CA2309688C/en not_active Expired - Fee Related
- 1998-11-09 AU AU13132/99A patent/AU747041B2/en not_active Ceased
- 1998-11-09 US US09/189,090 patent/US6319913B1/en not_active Expired - Lifetime
-
2000
- 2000-05-10 NO NO20002422A patent/NO20002422L/en not_active Application Discontinuation
-
2001
- 2001-09-24 US US09/963,287 patent/US6579865B2/en not_active Expired - Lifetime
-
2003
- 2003-03-12 US US10/389,715 patent/US7157097B2/en not_active Expired - Lifetime
-
2004
- 2004-10-28 JP JP2004313201A patent/JP2005047932A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2005047932A (en) | 2005-02-24 |
IL136042A0 (en) | 2001-05-20 |
DK1510213T3 (en) | 2009-03-23 |
KR20010031984A (en) | 2001-04-16 |
AU747041B2 (en) | 2002-05-09 |
EP1510213A3 (en) | 2005-03-23 |
KR100648536B1 (en) | 2006-11-24 |
CA2309688C (en) | 2007-04-24 |
DE69840426D1 (en) | 2009-02-12 |
EP1030668A4 (en) | 2002-09-25 |
EP1510213B1 (en) | 2008-12-31 |
BR9814014A (en) | 2000-09-26 |
EP1510213A2 (en) | 2005-03-02 |
US6319913B1 (en) | 2001-11-20 |
CN1172674C (en) | 2004-10-27 |
ATE418988T1 (en) | 2009-01-15 |
US20030166625A1 (en) | 2003-09-04 |
PT1510213E (en) | 2009-02-12 |
AU1313299A (en) | 1999-05-31 |
NO20002422L (en) | 2000-06-21 |
WO1999024041A1 (en) | 1999-05-20 |
EP1030668A1 (en) | 2000-08-30 |
JP2001522804A (en) | 2001-11-20 |
BR9814014B1 (en) | 2014-10-07 |
US6579865B2 (en) | 2003-06-17 |
JP4139860B2 (en) | 2008-08-27 |
CN1285749A (en) | 2001-02-28 |
AU747041C (en) | 1999-05-31 |
IL136042A (en) | 2005-12-18 |
US20020058650A1 (en) | 2002-05-16 |
NO20002422D0 (en) | 2000-05-10 |
NZ504423A (en) | 2003-04-29 |
US7157097B2 (en) | 2007-01-02 |
ES2318233T3 (en) | 2009-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2309688A1 (en) | Penetration enhancing and irritation reducing systems | |
AU6607898A (en) | Transdermal therapeutic system | |
AU4923500A (en) | Device and method for increasing the transdermal permeation of medicaments | |
GEP20043171B (en) | Skin with a Minimal Systemic Effect | |
EP2020228A3 (en) | Skin cosmetic composition | |
PT957900E (en) | COMPOSITIONS AND METHODS FOR TOPIC APPLICATION OF THERAPEUTIC AGENTS | |
WO2000027381A3 (en) | Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions | |
AU2002342765A1 (en) | Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations | |
MX9603596A (en) | Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds. | |
UA35611C2 (en) | Topical composition for inhibiting hair growth in mammals, method for application and topical composition for delivering water-soluble pharmaceutical to skin | |
ZA200005413B (en) | Cholesterol sulfate compositions for enhancement of stratum corneum function. | |
EP0197358A3 (en) | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation | |
WO1999002143A3 (en) | Medicament comprising adenosine | |
WO1997030714A3 (en) | Topical pharmaceutical composition containing heparin | |
WO1999021574A3 (en) | Enhancement of morphogen activity | |
WO1998031712A3 (en) | Chitosan-conjugates with acidic chelate-complex forming agents | |
AU3631500A (en) | N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent | |
CA2279962A1 (en) | An anhydrous antiperspirant composition comprising a pentane propellant | |
FR2719475B1 (en) | Cosmetic and / or dermatological composition with cationic polymeric gelling agent, its uses in particular for depigmentation of the skin. | |
BR9714945A (en) | Topically applicable composition for introducing peptidaceous drugs into living organisms | |
WO2000002601A3 (en) | Transdermal delivery system | |
AU1290797A (en) | Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation | |
IL136807A0 (en) | Topical carbamazepine formulation and methods of use | |
ZA977895B (en) | Transdermal therapeutic system having an active compound combination comprising oestriol. | |
WO2002024156A3 (en) | Topical skin-treatment agent containing arginase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20161109 |